Gapping down
In reaction to disappointing earnings/guidance: DDS -10.3%, ASTI -7.9%, SORL -4.6%, MOBI -4.6%, AUMN -3.1%
M&A news: HOT -5.1% (Starwood Hotels to be acquired by Marriott (MAR) for ~$12.2 bln, or roughly $79.88/share in cash/stock), SYT -2.8% (weakness pre-mkt, may be giving back gains from Friday after no new news on M&A talks), MAR -1.2% (see HOT)
Select Travel and Leisure related names showing weakness after Paris attacks: CCL -1.9%, EXPE -1.8%, CTRP -1.6%, DAL -1.5%, ALK -1.2%, RCL -0.8%
Other news: CLVS -59% (announces that the FDA requested additional clinical data for use in the efficacy analysis for both the 500mg and 625mg BID dose patient groups for rociletinib), KBIO -52.2% (to wind down operations, engages the Brenner Group to lead efforts), HOT -5.3% ( to be acquired by Marriott (MAR) for ~$12.2 bln, or roughly $79.88/share in cash/stock), FIVE -4.8% (downgraded to Hold from Buy at Deutsche Bank), RPTP -4.8% (provides additional results on RP103, re-iterating there was no difference in the response rate between RP103 and placebo), NBG -1.9% (cont weakness), KKR -1.5% (filess for ~2.63 mln share offering of common units by selling unitholders), TI -1% (Telecom Italia receives request from Vivendi (VIVHY) to supplement the agenda of upcoming shareholders meeting; Vivendi planning to appoint four directors)
Analyst comments: CNHI -4.7% (downgraded to Underweight from Neutral at JP Morgan ), MNKD -3.7% (downgraded to Neutral at Griffin Securities ), BBY -1.4% (downgraded to Sector Perform at RBC Capital Mkts
)
In reaction to disappointing earnings/guidance: DDS -10.3%, ASTI -7.9%, SORL -4.6%, MOBI -4.6%, AUMN -3.1%
M&A news: HOT -5.1% (Starwood Hotels to be acquired by Marriott (MAR) for ~$12.2 bln, or roughly $79.88/share in cash/stock), SYT -2.8% (weakness pre-mkt, may be giving back gains from Friday after no new news on M&A talks), MAR -1.2% (see HOT)
Select Travel and Leisure related names showing weakness after Paris attacks: CCL -1.9%, EXPE -1.8%, CTRP -1.6%, DAL -1.5%, ALK -1.2%, RCL -0.8%
Other news: CLVS -59% (announces that the FDA requested additional clinical data for use in the efficacy analysis for both the 500mg and 625mg BID dose patient groups for rociletinib), KBIO -52.2% (to wind down operations, engages the Brenner Group to lead efforts), HOT -5.3% ( to be acquired by Marriott (MAR) for ~$12.2 bln, or roughly $79.88/share in cash/stock), FIVE -4.8% (downgraded to Hold from Buy at Deutsche Bank), RPTP -4.8% (provides additional results on RP103, re-iterating there was no difference in the response rate between RP103 and placebo), NBG -1.9% (cont weakness), KKR -1.5% (filess for ~2.63 mln share offering of common units by selling unitholders), TI -1% (Telecom Italia receives request from Vivendi (VIVHY) to supplement the agenda of upcoming shareholders meeting; Vivendi planning to appoint four directors)
Analyst comments: CNHI -4.7% (downgraded to Underweight from Neutral at JP Morgan ), MNKD -3.7% (downgraded to Neutral at Griffin Securities ), BBY -1.4% (downgraded to Sector Perform at RBC Capital Mkts
)